Pharmaceuticals in Australia

Date: June 30, 2017
Pages: 41
Price:
US$ 350.00 US$ 315.00
Offer valid until September 1, 2017!
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P395686B0E6EN
Leaflet:

Download PDF Leaflet

Pharmaceuticals in Australia
Pharmaceuticals in Australia

SUMMARY

Pharmaceuticals in Australia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS

Essential resource for top-line data and analysis covering the Australia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

KEY HIGHLIGHTS
  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
  • The Australian pharmaceuticals market had total revenues of $22.9bn in 2016, representing a compound annual growth rate (CAGR) of 1.9% between 2012 and 2016.
  • Factors driving growth in Australia’s pharmaceuticals are similar to many other developed markets, including an increasingly elderly population and its associated disease burden, along with well-defined regulatory guidelines and the rising prevalence of non-communicable diseases due to an increasingly sedentary way of life.
  • Alternative treatments pose a serious substitution threat in Australia, to the distaste of the medical profession. The Medical Journal of Australia found controversial and unproven treatments for menopause are being used by nearly 500,000 Australian women, most of who were directed towards the treatments by doctors.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Australia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Australia
  • Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Australia pharmaceuticals market with five year forecasts
REASONS TO BUY
  • What was the size of the Australia pharmaceuticals market by value in 2016?
  • What will be the size of the Australia pharmaceuticals market in 2021?
  • What factors are affecting the strength of competition in the Australia pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitiors in Australia's pharmaceuticals market?
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Aspen Pharmacare Holdings Ltd
AstraZeneca PLC
GlaxoSmithKline Plc
Pfizer Inc.
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Australia pharmaceuticals market value: $ billion, 2012–16
Table 2: Australia pharmaceuticals market geography segmentation: $ billion, 2016
Table 3: Australia pharmaceuticals market share: % share, by value, 2016
Table 4: Australia pharmaceuticals market value forecast: $ billion, 2016–21
Table 5: Aspen Pharmacare Holdings Ltd: key facts
Table 6: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 7: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 8: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 9: AstraZeneca PLC: key facts
Table 10: AstraZeneca PLC: key financials ($)
Table 11: AstraZeneca PLC: key financial ratios
Table 12: GlaxoSmithKline Plc: key facts
Table 13: GlaxoSmithKline Plc: key financials ($)
Table 14: GlaxoSmithKline Plc: key financials (£)
Table 15: GlaxoSmithKline Plc: key financial ratios
Table 16: Pfizer Inc.: key facts
Table 17: Pfizer Inc.: key financials ($)
Table 18: Pfizer Inc.: key financial ratios
Table 19: Australia size of population (million), 2012–16
Table 20: Australia gdp (constant 2005 prices, $ billion), 2012–16
Table 21: Australia gdp (current prices, $ billion), 2012–16
Table 22: Australia inflation, 2012–16
Table 23: Australia consumer price index (absolute), 2012–16
Table 24: Australia exchange rate, 2012–16

LIST OF FIGURES

Figure 1: Australia pharmaceuticals market value: $ billion, 2012–16
Figure 2: Australia pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 3: Australia pharmaceuticals market share: % share, by value, 2016
Figure 4: Australia pharmaceuticals market value forecast: $ billion, 2016–21
Figure 5: Forces driving competition in the pharmaceuticals market in Australia, 2016
Figure 6: Drivers of buyer power in the pharmaceuticals market in Australia, 2016
Figure 7: Drivers of supplier power in the pharmaceuticals market in Australia, 2016
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Australia, 2016
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Australia, 2016
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Australia, 2016
Figure 11: Aspen Pharmacare Holdings Ltd: revenues & profitability
Figure 12: Aspen Pharmacare Holdings Ltd: assets & liabilities
Figure 13: AstraZeneca PLC: revenues & profitability
Figure 14: AstraZeneca PLC: assets & liabilities
Figure 15: GlaxoSmithKline Plc: revenues & profitability
Figure 16: GlaxoSmithKline Plc: assets & liabilities
Figure 17: Pfizer Inc.: revenues & profitability
Figure 18: Pfizer Inc.: assets & liabilities

COMPANIES MENTIONED

Aspen Pharmacare Holdings Ltd
AstraZeneca PLC
GlaxoSmithKline Plc
Pfizer Inc.
Skip to top


OTC Pharmaceuticals in Australia US$ 315.00 Sep, 2016 · 39 pages
Pharmaceuticals Global Industry Almanac 2017 US$ 2,545.75 May, 2017 · 505 pages

Ask Your Question

Pharmaceuticals in Australia
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: